Klapdor B, Ewig S
Thoraxzentrum Ruhrgebiet, Kliniken für Pneumologie und Infektiologie, EVK Herne und Augusta-Krankenanstalt Bochum, Bergstr. 26, 44791, Bochum, Deutschland.
Med Klin Intensivmed Notfmed. 2012 Apr;107(3):179-84. doi: 10.1007/s00063-011-0066-x. Epub 2012 Mar 22.
Chronic obstructive lung disease (COPD) is a leading cause of death worldwide. In patients with acute exacerbations admitted to an intensive care unit (ICU), potentially pathogenic microorganisms can be found in approximately 50%, with Haemophilus influenzae and Streptococcus pneumoniae as the leading strains, followed by enterobacteria and Pseudomonas aeruginosa. Viruses can also be detected in a large proportion of patients. The indication for antimicrobial treatment of acutely exacerbated COPD is still controversial but recommended by guidelines for all patients admitted to an ICU. Appropriate agents for an empiric initial treatment are penicillins + betalactamase inhibitor, 2(nd) and 3(rd) generation cephalosporins, carbapenems, and quinolones. Antimicrobial treatment should be adjusted according to the results of microbial investigation of sputum or endotracheal aspirate.
慢性阻塞性肺疾病(COPD)是全球主要的死亡原因之一。在入住重症监护病房(ICU)的急性加重患者中,约50%可发现潜在致病微生物,其中流感嗜血杆菌和肺炎链球菌是主要菌株,其次是肠杆菌和铜绿假单胞菌。在很大一部分患者中也可检测到病毒。COPD急性加重期抗菌治疗的指征仍存在争议,但指南建议对所有入住ICU的患者进行抗菌治疗。经验性初始治疗的合适药物包括青霉素+β-内酰胺酶抑制剂、第二代和第三代头孢菌素、碳青霉烯类和喹诺酮类。应根据痰或气管内吸出物的微生物检测结果调整抗菌治疗。